Autopsy report · NCT05832255
An Investigation of Psilocybin on Behavioural and Cognitive Symptoms of Adults With Fragile X Syndrome
Cause of deathOther
“Indefinite hold due to protocol revisions relating to the exclusion criteria for concurrent medications.”
Life of this trial
- Suspended: paused, and may or may not restart.
- 10 participants planned (an estimate, not an actual count).
Vital statistics
- Status
- Suspended
- Phase
- Phase 2
- Sponsor
- Nova Mentis Life Science Corp
- Sponsor type
- Industry
- Conditions
- Fragile X Syndrome; Behavior; Cognitive Dysfunction
- Interventions
- Psilocybin, 1.5 mg
- Participants
- 10 (planned, not actual)
- Sites
- 1
- Countries
- Canada
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.